.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Mallinckrodt
Healthtrust
Cerilliant
Johnson and Johnson
QuintilesIMS
US Army
Chinese Patent Office
Dow

Generated: September 25, 2017

DrugPatentWatch Database Preview

Peginesatide acetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for peginesatide acetate and what is the scope of peginesatide acetate freedom to operate?

Peginesatide acetate
is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peginesatide acetate has one hundred and seven patent family members in thirty-two countries.

Summary for Generic Name: peginesatide acetate

Tradenames:2
Patents:6
Applicants:1
NDAs:1
Clinical Trials: see list943
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:peginesatide acetate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-002Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-002Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-008Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-004Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-007Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-002Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: peginesatide acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,304,391Peptides that bind to the erythropoietin receptor► Subscribe
8,729,030Peptides that bind to the erythropoietin receptor► Subscribe
7,855,175Peptides that bind to the erythropoietin receptor► Subscribe
8,324,159Erythropoietin receptor peptide formulations and uses► Subscribe
7,906,485Erythropoietin receptor peptide formulations and uses► Subscribe
8,592,365Spacer moiety for poly(ethylene glycol) modified peptide based compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: peginesatide acetate

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004101611► Subscribe
Australia2004238364► Subscribe
Iceland2683► Subscribe
Iceland8165► Subscribe
Cyprus1113442► Subscribe
Eurasian Patent Organization200702656► Subscribe
Japan2010536858► Subscribe
Serbia20050838► Subscribe
Japan2008542399► Subscribe
Australia2004238870► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
McKesson
Novartis
Colorcon
Julphar
Daiichi Sankyo
Johnson and Johnson
Medtronic
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot